Condition: Breast Cancer Female · Sponsor: University of Virginia
This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
This description comes directly from the study's public registry record.
Meagan Miller · 434-243-8101 · aey8fc@uvahealth.org
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
| University of Virginia Community Health | Culpeper, Virginia, United States | Recruiting |
| INOVA Schar Cancer | Fairfax, Virginia, United States | Recruiting |
| Riverside Health System | Newport News, Virginia, United States | Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06507618